Skip to main content

Table 2 Factors associated with long-term outcomes pancreatic cancer derived from univariate analysis and multivariate analysis (n = 1,082)

From: Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients

  Hazard ratio 95% CI P-value
Univariate analysis    
  Age < 65 years old 0.80 0.67 ‒ 0.94 0.0072
  Female 0.95 0.82 ‒ 1.11 0.5648
  Surgery (vs. Chemotherapy) 0.31 0.24 ‒ 0.40 <0.0001
  Surgery (vs. BSC) 0.11 0.08 ‒ 0.14 <0.0001
  Chemotherapy (vs. BSC) 0.34 0.29 ‒ 0.40 <0.0001
  Tumor Location (Head) 0.77 0.66 ‒ 0.91 0.0015
  Group B (2006–2010) 0.81 0.69 ‒ 0.94 0.0063
  Stage I‒III 0.32 0.25 ‒ 0.40 <0.0001
Multivariate analysis    
  Age < 65 years old 0.94 0.79 ‒ 1.11 0.4581
  Surgery (vs. Chemotherapy) 0.43 0.33 ‒ 0.56 <0.0001
  Surgery (vs. BSC) 0.13 0.10 ‒ 0.18 <0.0001
  Chemotherapy (vs. BSC) 0.31 0.26 ‒ 0.37 <0.0001
  Tumor Location (Head) 0.83 0.71 ‒ 0.98 0.0294
  Group B (2006–2010) 0.91 0.78 ‒ 1.06 0.2357
  Stage I‒III 0.46 0.36 ‒ 0.59 <0.0001
  1. BSC, best supportive care.